Crossmark

Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s43018-024-00822-0

Published Online: 2024-09-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Kaiwen

Zhong, Wenlong

Fan, Jinhai

Wang, Shaogang

Yu, Dexin

Xu, Tao

Lyu, Jiaju

Wu, Shaoxu

Qin, Tao

Wu, Zhuo

Xu, Longhao

Wu, Kaijie

Liu, Zheng

Hu, Zhiquan

Li, Fan

Wang, Jinyou

Wang, Qi

Min, Jie

Zhang, Zhiqiang

Yu, Luping

Ding, Sentai

Huang, Longfei

Zhao, Tingting

Huang, Jian https://orcid.org/0000-0002-1296-9316
Lin, Tianxin https://orcid.org/0000-0003-3180-8697
License Information

Text and Data Mining valid from 2024-09-10

Version of Record valid from 2024-09-10
More Information

Article History

Received: 9 December 2023

Accepted: 9 August 2024

First Online: 10 September 2024

Competing interests

: L.H. and T.Z. were employees of GloriousMed at the time of the study. The other authors declare no competing interests.

Document is current

Any future updates will be listed below